T-cell Acute Lymphoblastic Leukemia Clinical Trials

31 clinical trials for T-cell Acute Lymphoblastic Leukemia across international registries, including 18 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma — RECRUITING · PHASE1
• Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen — RECRUITING · PHASE1
• Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) — RECRUITING · PHASE2
• A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) — RECRUITING · PHASE2
• A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) — RECRUITING · PHASE2
• Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL — RECRUITING · PHASE2
• NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL — RECRUITING · PHASE1
• Universal 4SCAR7U Targeting CD7-positive Malignancies — RECRUITING · PHASE1
• Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies — RECRUITING · PHASE1
• Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells — RECRUITING · PHASE1
• Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma — RECRUITING · PHASE1
• Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients — RECRUITING · PHASE2
• Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL — RECRUITING · PHASE1
• Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma — RECRUITING · PHASE1
• Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies — RECRUITING · PHASE1
• Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention — RECRUITING · PHASE2
• A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 — RECRUITING
• Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells — RECRUITING · PHASE1
• A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma — NOT_YET_RECRUITING · PHASE1
• Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL — COMPLETED · PHASE1
• Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies — COMPLETED · PHASE1
• XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia — TERMINATED · PHASE1
• Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia — TERMINATED · PHASE1
• Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia — OTHER
• A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL — WITHDRAWN · PHASE1
• CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia — OTHER · PHASE1
• Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances — OTHER · PHASE1
• Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies — OTHER · PHASE1
• A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL — COMPLETED · PHASE1
• Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden. — COMPLETED

Refine this search